Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Post-Mkt 03-02 16:35:30 EST

3.63

-0.04

-1.09%

盘后3.63

+0.000.00%

16:34 EST

High3.71	Low3.46	Vol13.88M
Open3.48	D1 Closing3.67	Amplitude6.81%
Mkt Cap1.91B	Tradable Cap1.51B	Total Shares527.40M
T/O50.09M	T/O Rate3.35%	Tradable Shares415.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":3.63,"timestamp":1772485200000,"preClose":3.67,"halted":0,"volume":13883599,"hourTrading":{"tag":"盘后","latestPrice":3.63,"preClose":3.63,"latestTime":"16:34 EST","volume":105204,"amount":381900.49333920004,"timestamp":1772487264339,"change":0,"changeRate":0,"amplitude":0.00832},"delay":0,"changeRate":-0.010899182561307912,"floatShares":415000000,"shares":527397997,"eps":-1.440975,"marketStatus":"Post-Mkt","change":-0.04,"latestTime":"03-02 16:35:30 EST","open":3.48,"high":3.71,"low":3.46,"amount":50090997.805674,"amplitude":0.06812,"askPrice":3.65,"askSize":520,"bidPrice":3.61,"bidSize":1702,"shortable":3,"etf":0,"ttmEps":-1.440975,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772499600000},"marketStatusCode":4,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":3.67,"preHourTrading":{"tag":"盘前","latestPrice":3.48,"preClose":3.67,"latestTime":"09:29 EST","volume":351704,"amount":1226795.780044,"timestamp":1772461799906,"change":-0.19,"changeRate":-0.051771,"amplitude":0.016349},"postHourTrading":{"tag":"盘后","latestPrice":3.63,"preClose":3.63,"latestTime":"16:34 EST","volume":105204,"amount":381900.49333920004,"timestamp":1772487264339,"change":0,"changeRate":0,"amplitude":0.00832},"volumeRatio":0.651869,"impliedVol":0.66,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/RXRX","defaultTab":"news","newsList":[{"id":"2614866651","title":"Recursion Pharmaceuticals Publishes 2025 Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2614866651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614866651?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:47","pubTimestamp":1772214434,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Inc. published a 2025 shareholder letter outlining business updates and priorities for 2026 and beyond. The letter reports an AI-enabled clinical proof of concept in familial adenomatous polyposis for REC-4881 and states that five clinical programs are advancing with defined differentiation and go/no-go criteria. The letter also cites more than $500 million in upfront and progress-based milestone payments to date from partnerships, including $213 million in cash inflows from Roche and Genentech and $134 million in cash inflows from Sanofi. The full letter can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3mX09H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","BK4609","RXRX","BK4611","BK4539"],"gpt_icon":1},{"id":"1195580149","title":"Nvidia-Linked Shares Fall. CoreWeave Plunged over 17%; Nebius Down 8%; APLD Down 5%; Nvidia Down 2.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195580149","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195580149?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:38","pubTimestamp":1772203090,"startTime":"0","endTime":"0","summary":"Nvidia-linked shares fell on Friday. CoreWeave plunged over 17%; Nebius down 8%; APLD down 5%; Nvidia down 2.5%.$CoreWeave(CRWV)$ expects capital expenditure to double this year, it said on Thursday,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"117a4290f3fb77553df3afbd7ffdef06","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDA","ARBE","CRNC","NNOX","SERV","RXRX","APLD","SOUN","TM","ARM","MU","NBIS","AUR","INVZ"],"gpt_icon":1},{"id":"2614043895","title":"Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2614043895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614043895?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:35","pubTimestamp":1772105700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 06:35 ET (11:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4139","BK4611","BK4539","RXRX","BK4548"],"gpt_icon":0},{"id":"2614695043","title":"Recursion Pharmaceuticals price target lowered to $6 from $7 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614695043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614695043?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:32","pubTimestamp":1772105527,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Neutral rating on the shares. The firm revised i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-6-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-price-target-lowered-to-6-from-7-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RXRX","BK4548","BK4611","BK4609","BK4539"],"gpt_icon":0},{"id":"2614069711","title":"Balanced Risk-Reward Keeps Recursion at Hold as Key Clinical Catalysts Remain Longer-Dated","url":"https://stock-news.laohu8.com/highlight/detail?id=2614069711","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614069711?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:25","pubTimestamp":1772069133,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Alec Stranahan has reiterated their neutral stance on RXRX stock, giving a Hold rating yesterday. Alec Stranahan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-keeps-recursion-at-hold-as-key-clinical-catalysts-remain-longer-dated-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-keeps-recursion-at-hold-as-key-clinical-catalysts-remain-longer-dated-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002270589.USD","LU1883839398.USD","LU1366192091.USD","LU0130102774.USD","LU0648000940.SGD","IE00B19Z3B42.SGD","LU0149725797.USD","LU0971096721.USD","BK4504","LU0256863811.USD","LU0321505439.SGD","LU0868494617.USD","IE0001KFT4U8.USD","LU0320765646.SGD","LU0787776722.HKD","LU1363072403.SGD","BK4139","BK4548","BK4539","LU1280957306.USD","LU0070302665.USD","LU0477156953.USD","IE00B19Z3581.USD","LU0130517989.USD","LU0648001328.SGD","LU0321505868.SGD","LU0683600562.USD","LU0052756011.USD","LU1035773651.USD","IE0034235188.USD","BK4581","LU1496350502.SGD","IE00BLSP4452.SGD","BK4559","LU0320765489.SGD","LU0310800965.SGD","BK4553","LU2129689605.HKD","BK4534","LU0306807586.USD","LU1668664300.SGD","LU0640476718.USD","LU1496350171.SGD","LU0211331839.USD","LU0203347892.USD","BK4609","LU0170899867.USD","LU1880398554.USD","IE00BBT3K403.USD","LU1069347547.HKD","LU1162221912.USD","IE00BZ1G4Q59.USD","RXRX","LU1894683348.USD","LU0203345920.USD","IE00B7SZLL34.SGD","LU1201861165.SGD","LU0130518102.USD","LU0417517546.SGD","LU0306806265.USD","LU1880398471.USD","BK4207","LU1074936037.SGD","LU0256863902.USD","IE00BKVL7J92.USD","IE00BFXG1179.USD","BK4588","LU1267930227.SGD","LU0130103400.USD","LU1791807156.HKD","LU1201861249.SGD","LU0053666078.USD","BK4611","LU0128525689.USD","LU0980610538.SGD","IE00BLSP4239.USD","LU1506573853.SGD","LU2265009873.SGD","BK4585","LU2133065610.SGD","LU0477156797.USD","LU2129689431.USD","LU0106831901.USD","LU1804176565.USD","LU1718418525.SGD","LU0098860793.USD","LU1894683264.USD","LU2129689514.USD","LU0208291251.USD","LU0234572021.USD","LU0314106906.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2614805310","title":"Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Penumbra (PEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614805310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614805310?lang=en_us&edition=fundamental","pubTime":"2026-02-26 04:00","pubTimestamp":1772049624,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Recursion Pharmaceuticals (RXRX – Research Report) and Penumbra (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-penumbra-pen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-recursion-pharmaceuticals-rxrx-and-penumbra-pen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","LU0128526141.USD","BK4609","BK4611","BK4137","BK4139","BK4539","LU0029874061.USD","RXRX","PEN","BK4585","XBI","BK4581","LABU","BK4082","BK4588"],"gpt_icon":0},{"id":"2614303929","title":"What's Behind The Jump In Recursion Pharmaceuticals Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303929","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614303929?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:54","pubTimestamp":1772034840,"startTime":"0","endTime":"0","summary":"Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/25/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/25/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50854848/whats-behind-the-jump-in-recursion-pharmaceuticals-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50854848/whats-behind-the-jump-in-recursion-pharmaceuticals-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","BK4611","BK4548","BK4609","BK4139","RXRX"],"gpt_icon":1},{"id":"2614808951","title":"Recursion Pharmaceuticals Q4 Loss Narrows, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2614808951","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614808951?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:54","pubTimestamp":1772020454,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  reported a Q4 loss Wednesday of $0.21 per diluted share, narrowing from a loss of $0.53 a year earlier.Analysts polled by FactSet expected a loss of $0.31.Revenue for the quarter ended Dec. 31 was $35.5 million, up from $4.5 million a year earlier.Analysts surveyed by FactSet expected $24.5 million.As of Dec. 31, Recursion said it had $753.9 million in cash and cash equivalents, which it expects to provide it with a cash runway through early 2028.Shares of the company were up more than 12% in recent Wednesday premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4611","BK4139","BK4609","BK4548","RXRX"],"gpt_icon":1},{"id":"2614089881","title":"Recursion Pharmaceuticals Inc - May Sell Class a Stock up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089881","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089881?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:46","pubTimestamp":1772020019,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RXRX","BK4539","BK4139","BK4611","BK4609","BK4548"],"gpt_icon":0},{"id":"2614108608","title":"Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2614108608","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614108608?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:44","pubTimestamp":1772019858,"startTime":"0","endTime":"0","summary":"Recursion Pharma Q4 revenue tops eatimates, helped by Sanofi paymentsOverviewClinical stage TechBio firm's Q4 operating revenue beat analyst expectationsNet income for Q4 exceeded analyst estimatesCom","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL1N3ZL0GD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4139","BK4548","BK4611","BK4539","RXRX"],"gpt_icon":1},{"id":"2614086139","title":"Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086139","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086139?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:37","pubTimestamp":1772019448,"startTime":"0","endTime":"0","summary":"Recursion's 2025 Cash Balance Was $753.9M With Expected Cash Runway Extending Into Early 2028","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50843855/recursions-2025-cash-balance-was-753-9m-with-expected-cash-runway-extending-into-early-2028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4609","BK4611","BK4139","BK4539","RXRX"],"gpt_icon":0},{"id":"2614086196","title":"Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086196","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086196?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:37","pubTimestamp":1772019435,"startTime":"0","endTime":"0","summary":"Earnings Flash (RXRX)Recursion Pharmaceuticals Posts Q4 Loss $0.21 a Share, vs. FactSet Est of $0.21 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RXRX","BK4548","BK4539","BK4609","BK4611"],"gpt_icon":0},{"id":"1155956762","title":"Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=1155956762","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155956762?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:34","pubTimestamp":1772019271,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biotechnology company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RXRX"],"gpt_icon":1},{"id":"2614908657","title":"Recursion Pharmaceuticals Q4 2025 EPS $(0.21) Beats $(0.27) Estimate, Sales $35.537M Beat $24.586M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614908657","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614908657?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:32","pubTimestamp":1772019121,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Q4 2025 EPS $(0.21) Beats $(0.27) Estimate, Sales $35.537M Beat $24.586M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50843522/recursion-pharmaceuticals-q4-2025-eps-0-21-beats-0-27-estimate-sales-35-537m-beat-24-586m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4548","BK4139","RXRX","BK4609","BK4611"],"gpt_icon":0},{"id":"2614108668","title":"BRIEF-Recursion Pharmaceuticals Q4 Operating Revenue USD 35.351 Million Vs. IBES Estimate USD 24.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614108668","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614108668?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019046,"startTime":"0","endTime":"0","summary":"Feb 25  - Recursion Pharmaceuticals Q4 operating income USD -108.335 million.Q4 net income USD -108.124 million vs. IBES estimate USD -131.1 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLXAB03CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4539","BK4139","BK4611","BK4609","BK4548"],"gpt_icon":0},{"id":"2614086635","title":"Recursion Q4 revenue hits USD 35.5 million, up 7.8x","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086635","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086635?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019040,"startTime":"0","endTime":"0","summary":"Recursion reported Q4 2025 total revenue of USD 35.5 million  and FY 2025 total revenue of USD 74.7 million . Q4 2025 net loss was USD 108.1 million, and FY 2025 net loss was USD 644.8 million. Cash, cash equivalents and restricted cash totaled USD 753.9 million at Dec. 31, 2025, with Recursion stating its expected cash runway extends into early 2028; FY 2025 net cash used in operating activities was USD 371.8 million and FY 2025 cash operating expense  was USD 399.2 million. On business updates, Recursion highlighted positive preliminary Phase 2 results for REC-4881 in familial adenomatous polyposis , including 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks , with 82% maintaining durable reductions after 12 weeks off therapy and a 53% median reduction from baseline. The company also said it achieved a fifth Sanofi milestone in February 2026 for a USD 4 million payment, bringing total payments received from the Sanofi partne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL1yK68Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4548","BK4112","BK4611","BK4609","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","BK4539","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","RXRX","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":1},{"id":"2614871086","title":"Recursion Pharmaceuticals Q4 Pretax Profit USD -108.104 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614871086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614871086?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLXAB03CD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4139","BK4548","BK4611","BK4539","RXRX"],"gpt_icon":0},{"id":"2614086806","title":"Recursion Pharmaceuticals Q4 Operating Revenue USD 35.351 Million VS. Ibes Estimate USD 24.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086806?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLXAB03CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RXRX","BK4548","BK4611","BK4609","BK4539"],"gpt_icon":0},{"id":"2614086150","title":"Recursion Pharmaceuticals Q4 EPS USD -0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086150","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086150?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLXAB03CD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RXRX","BK4548","BK4611","BK4609","BK4539"],"gpt_icon":0},{"id":"2614630086","title":"Press Release: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614630086","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614630086?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:30","pubTimestamp":1772019000,"startTime":"0","endTime":"0","summary":"-- Delivered first clinical validation of the Recursion full stack AI. Operating System in FAP, demonstrating translation from AI-driven. biological insight to meaningful patient outcomes; multiple clinical and. -- Achieved fifth program milestone with Sanofi, totaling $134 million in. payments to date; five Recursion discovery program packages have been. accepted to date, establishing a growing joint portfolio of novel. -- $754 million of cash and cash equivalents; exceeded original cost savings. guidance and now expect runway into early 2028 without additional. SALT LAKE CITY, Feb. 25, 2026  -- Recursion  a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.Summary of Business Highlights: Driving a diversified pipeline powered by the end-to-end AI-native Recursion OS - wholly-owned and partnered programs. 2025 Wholly Owned Pipeline Achie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"101ec87b89813fb9d95dbaf13286caff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4528","BK4539","BK4587","BK4611","BK4609","BK4548","BK4588","BK4139","BK4551","BK4585","BK4023","AIYY","BK4543","BK4007"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":0.0731},{"period":"1month","weight":-0.179},{"period":"3month","weight":-0.2073},{"period":"6month","weight":-0.2191},{"period":"1year","weight":-0.5215},{"period":"ytd","weight":-0.1027}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035717},{"month":2,"riseRate":0.4,"avgChangeRate":0.049361},{"month":3,"riseRate":0,"avgChangeRate":-0.270652},{"month":4,"riseRate":0.25,"avgChangeRate":-0.144468},{"month":5,"riseRate":0.4,"avgChangeRate":0.084296},{"month":6,"riseRate":0.6,"avgChangeRate":0.136566},{"month":7,"riseRate":0.8,"avgChangeRate":0.206054},{"month":8,"riseRate":0.2,"avgChangeRate":-0.126569},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050486},{"month":10,"riseRate":0.2,"avgChangeRate":-0.079168},{"month":11,"riseRate":0.4,"avgChangeRate":0.028843},{"month":12,"riseRate":0.2,"avgChangeRate":-0.000986}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}